Comments to FDA: Evaluating Drug Names for Similarities Share page: Docket Number: 2003N-0201 Letter to Daniel E. Troy, Esq. regarding whether there should be different trade-name evaluation procedures for different classes of drugs (Rx versus OTC). Download Document Issues: OTC Medicines Other Issues Branding Related Posts Press Releases and Statements CHPA Responds to HHS/FDA Announcement to Phase Out Petroleum-based Synthetic Dyes from America’s Food Supply Apr 22, 2025 Press Releases and Statements Health In Hand Foundation Announces Call for Nominations: 2025 U.S. Self-Care Marketing Awards Apr 22, 2025 Press Releases and Statements CHPA Applauds White House Executive Order Prioritizing Lower Drug Costs and Access to Self-Care Apr 17, 2025